Complete financial analysis of PharmaEngine, Inc. (4162.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaEngine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Spirent Communications plc (SPT.L) Income Statement Analysis – Financial Results
- Vishnu Chemicals Limited (VISHNU.BO) Income Statement Analysis – Financial Results
- EDP – Energias de Portugal, S.A. (ELCPF) Income Statement Analysis – Financial Results
- Physiomics Plc (PYC.L) Income Statement Analysis – Financial Results
- Twin Vee PowerCats, Inc. (TVPC) Income Statement Analysis – Financial Results
PharmaEngine, Inc. (4162.TWO)
About PharmaEngine, Inc.
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 767.67M | 654.38M | 654.84M | 1.06B | 314.04M | 293.43M | 853.68M | 1.13B | 507.24M | 228.99M | 37.40M | 184.03M | 320.05M | 0.00 | 0.00 |
| Cost of Revenue | 48.70M | 49.70M | 37.07M | 37.23M | 31.80M | 12.88M | 2.84M | 2.00M | 6.84M | 7.01M | 20.22M | 12.33M | 8.33M | 0.00 | 0.00 |
| Gross Profit | 718.97M | 604.68M | 617.76M | 1.02B | 282.24M | 280.55M | 850.84M | 1.13B | 500.41M | 221.98M | 17.18M | 171.70M | 311.73M | 0.00 | 0.00 |
| Gross Profit Ratio | 93.66% | 92.41% | 94.34% | 96.47% | 89.87% | 95.61% | 99.67% | 99.82% | 98.65% | 96.94% | 45.93% | 93.30% | 97.40% | 0.00% | 0.00% |
| Research & Development | 310.28M | 181.88M | 136.89M | 95.73M | 130.79M | 124.87M | 121.90M | 194.76M | 114.74M | 114.90M | 93.92M | 75.42M | 30.13M | 74.18M | 86.72M |
| General & Administrative | 92.97M | 94.95M | 81.67M | 76.23M | 83.73M | 77.40M | 75.75M | 102.50M | 58.34M | 36.53M | 62.74M | 46.65M | 39.28M | 17.78M | 19.53M |
| Selling & Marketing | 38.54M | 45.10M | 36.73M | 37.12M | 35.11M | 35.83M | 40.22M | 27.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.51M | 140.06M | 118.40M | 113.35M | 118.84M | 113.23M | 115.97M | 129.90M | 58.34M | 36.53M | 62.74M | 46.65M | 39.28M | 17.78M | 19.53M |
| Other Expenses | 0.00 | 84.23M | 167.50M | -98.39M | 17.17M | 121.33M | -115.98M | 29.78M | 79.67M | 53.77M | 21.64M | 803.00K | 5.17M | 43.37M | 7.33M |
| Operating Expenses | 441.79M | 321.94M | 255.29M | 209.07M | 249.63M | 238.11M | 237.87M | 324.66M | 173.08M | 151.43M | 156.66M | 122.07M | 69.41M | 91.96M | 106.25M |
| Cost & Expenses | 490.49M | 371.64M | 292.36M | 246.31M | 281.43M | 250.99M | 240.71M | 326.66M | 179.92M | 158.44M | 176.88M | 134.39M | 77.74M | 91.96M | 106.25M |
| Interest Income | 54.32M | 25.57M | 15.42M | 41.61M | 67.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01M | 1.22M | 153.00K | 114.00K |
| Interest Expense | 310.00K | 77.00K | 212.00K | 443.00K | 112.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | 36.00K |
| Depreciation & Amortization | 9.02M | 8.61M | 10.26M | 12.56M | 6.71M | 2.93M | 3.05M | 3.00M | 1.63M | 280.00K | 338.00K | 530.00K | 658.00K | 1.60M | 1.98M |
| EBITDA | 347.31M | 401.15M | 555.87M | 765.48M | 56.49M | 166.70M | 616.02M | 811.12M | 328.96M | 70.83M | -139.15M | 50.06M | 262.61M | -46.53M | -96.69M |
| EBITDA Ratio | 45.24% | 61.30% | 84.85% | 72.49% | 17.99% | 15.46% | 72.16% | 71.48% | 64.85% | 30.93% | -372.05% | 27.26% | 82.05% | 0.00% | 0.00% |
| Operating Income | 277.18M | 392.55M | 545.39M | 752.92M | 49.78M | 42.44M | 612.97M | 808.12M | 327.33M | 70.55M | -139.48M | 49.63M | 242.32M | -91.96M | -106.25M |
| Operating Income Ratio | 36.11% | 59.99% | 83.29% | 71.30% | 15.85% | 14.46% | 71.80% | 71.21% | 64.53% | 30.81% | -372.95% | 26.97% | 75.71% | 0.00% | 0.00% |
| Total Other Income/Expenses | 60.79M | -84.00K | 3.00K | -57.23M | 17.06M | 121.33M | -115.98M | 29.78M | 79.67M | 53.77M | 21.64M | -645.00K | 19.63M | 43.81M | 7.54M |
| Income Before Tax | 337.97M | 392.47M | 545.40M | 752.48M | 49.67M | 163.77M | 496.99M | 837.91M | 406.99M | 124.32M | -117.85M | 48.99M | 261.95M | -48.15M | -98.70M |
| Income Before Tax Ratio | 44.03% | 59.97% | 83.29% | 71.26% | 15.82% | 55.81% | 58.22% | 73.84% | 80.24% | 54.29% | -315.10% | 26.62% | 81.85% | 0.00% | 0.00% |
| Income Tax Expense | 63.32M | 73.68M | 119.36M | 148.19M | 7.12M | 34.41M | 109.92M | 148.28M | 12.97M | 729.00K | 0.00 | 17.00K | -23.76M | 43.83M | 7.58M |
| Net Income | 274.65M | 318.78M | 426.03M | 604.28M | 42.55M | 129.36M | 387.06M | 689.63M | 394.02M | 123.59M | -117.85M | 48.99M | 285.71M | -48.15M | -98.70M |
| Net Income Ratio | 35.78% | 48.72% | 65.06% | 57.22% | 13.55% | 44.09% | 45.34% | 60.77% | 77.68% | 53.97% | -315.10% | 26.62% | 89.27% | 0.00% | 0.00% |
| EPS | 1.91 | 2.22 | 2.95 | 4.15 | 0.29 | 0.88 | 2.63 | 4.71 | 2.69 | 0.85 | -0.88 | 0.40 | 2.73 | -0.56 | -1.53 |
| EPS Diluted | 1.91 | 2.22 | 2.94 | 4.14 | 0.29 | 0.88 | 2.62 | 4.69 | 2.67 | 0.84 | -0.87 | 0.40 | 2.73 | -0.56 | -1.53 |
| Weighted Avg Shares Out | 143.61M | 143.60M | 144.54M | 145.62M | 145.69M | 147.12M | 147.11M | 146.52M | 146.51M | 144.78M | 134.68M | 121.15M | 104.50M | 86.24M | 64.67M |
| Weighted Avg Shares Out (Dil) | 143.74M | 143.70M | 144.74M | 145.90M | 145.73M | 147.60M | 147.76M | 147.14M | 147.75M | 147.19M | 135.17M | 123.68M | 104.50M | 86.24M | 64.67M |
Source: https://incomestatements.info
Category: Stock Reports